ストックスクリーナーアプリを入手
1.09
2.83%
0.03
前日終値:
$1.06
開ける：
$1.06
24時間の取引高:
149.20K
Relative Volume:
1.94
時価総額：
$29.87M
収益：
-
当期純損益:
$-37.38M
株価収益率:
-0.8738
EPS:
-1.2474
ネットキャッシュフロー:
$-35.50M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-15.50%
6か月 パフォーマンス:
-5.22%
1年 パフォーマンス:
-20.44%
1日の値動き範囲:
$1.01
$1.11
1週間の範囲:
$1.01
$1.1199
52週間の値動き範囲:
$1.01
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
名前
An 2 Therapeutics Inc
セクター
電話
(650) 331-9090
住所
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
ANTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.09 | 29.05M | 0 | -37.38M | -35.50M | -1.2474 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2024-08-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-12 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
すべてを表示
An 2 Therapeutics Inc (ANTX) 最新ニュース
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis - Business Wire
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths - ABC News
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - GlobeNewswire
Cognition (NASDAQ: CGTX) completes Phase 2 enrollment at 540; 15% on Leqembi or Kisunla - Stock Titan
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRCSlideshow (NASDAQ:XLO) 2025-11-11 - Seeking Alpha
Intellia Therapeutics Presents Positive Pooled Phase 1/2 - GlobeNewswire
Cadrenal Therapeutics, Inc. - TradingView
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for - GlobeNewswire
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan
ASH 2025: Beam Therapeutics (NASDAQ: BEAM) to share updated BEAM-101 sickle cell data - Stock Titan
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewswire
Xilio (Nasdaq: XLO) late-breaking Phase 2 vilastobart poster at SITC on MSS mCRC, high pTMB - Stock Titan
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - Yahoo Finance
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules - Business Wire
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics
BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewswire
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - BioSpace
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Yahoo Finance
Kyverna Therapeutics to Host Conference Call on Interim - GlobeNewswire
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 - Yahoo Finance
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria - GlobeNewswire
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) - The Manila Times
RAPT Therapeutics to Report Topline Data from Phase 2 - GlobeNewswire
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting - Yahoo Finance
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - BioSpace
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results - TradingView
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round - Business Wire
Verrica Pharmaceuticals to Present New Data on VP-315 from - GlobeNewswire
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - GlobeNewswire
Viking Therapeutics Stock: A Speculative Buy (NASDAQ:VKTX) - Seeking Alpha
Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results - GlobeNewswire
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - GlobeNewswire
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire
Aarvik Therapeutics Announces Successful Series Seed 2 Financing Round - Business Wire
Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha
United Therapeutics (UTHR) Phase 3 TETON-2 Results Slideshow (NASDAQ:UTHR) 2025-09-28 - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial - MSN
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic - GlobeNewswire
Phase 2 Colorectal Cancer Trial Results: Leap Therapeutics' Sirexatamab Study Data Coming at ESMO 2025 - Stock Titan
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data - Yahoo Finance
Allarity Therapeutics Presents New Phase 2 Clinical Data - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
1.13%
大文字化:
|
ボリューム (24 時間):